BR100 Increased By (0.85%)
BR30 Increased By (0.42%)
KSE100 Increased By (0.87%)
KSE30 Increased By (0.83%)
AGHA 6.03 Increased By ▲ 0.01 (0.17%)
BECO 3.86 Increased By ▲ 0.05 (1.31%)
BML 61.00 Increased By ▲ 4.56 (8.08%)
BOP 28.09 Decreased By ▼ -0.01 (-0.04%)
CNERGY 11.74 Decreased By ▼ -0.54 (-4.4%)
CSIL 5.30 Increased By ▲ 0.01 (0.19%)
FCCL 54.46 Increased By ▲ 0.65 (1.21%)
FFL 13.07 Increased By ▲ 0.27 (2.11%)
FNEL 1.11 Decreased By ▼ -0.01 (-0.89%)
KEL 5.63 Decreased By ▼ -0.01 (-0.18%)
KOSM 5.34 Decreased By ▼ -0.04 (-0.74%)
LOTCHEM 23.83 Increased By ▲ 0.28 (1.19%)
MLCF 92.98 Increased By ▲ 1.02 (1.11%)
NBP 163.20 Increased By ▲ 0.96 (0.59%)
NCPL 48.27 Decreased By ▼ -0.64 (-1.31%)
NPL 49.71 Decreased By ▼ -0.80 (-1.58%)
OGDC 303.63 Increased By ▲ 1.95 (0.65%)
PACE 8.97 Decreased By ▼ -0.16 (-1.75%)
PAEL 31.91 Increased By ▲ 0.10 (0.31%)
PIBTL 12.74 Decreased By ▼ -0.04 (-0.31%)
PPL 212.91 Increased By ▲ 0.85 (0.4%)
PRL 84.34 Decreased By ▼ -2.92 (-3.35%)
PTC 44.99 Increased By ▲ 1.03 (2.34%)
SSGC 22.83 Decreased By ▼ -0.03 (-0.13%)
TBL 8.88 Decreased By ▼ -0.03 (-0.34%)
TELE 6.50 Increased By ▲ 0.06 (0.93%)
TPL 24.26 Increased By ▲ 0.17 (0.71%)
TPLP 11.99 Decreased By ▼ -0.17 (-1.4%)
TREET 23.14 Decreased By ▼ -0.36 (-1.53%)
TRG 51.47 Decreased By ▼ -0.40 (-0.77%)
Business & Finance

Ebola vaccine trial 'interrupted' due to joint pains

Published Updated

imageISLAMABAD: The clinical trial of an Ebola vaccine in Switzerland has been interrupted after some patients complained of joint pains in their hands and feet.

The trial was stopped one week early in all 59 volunteers "as a measure of precaution", the University of Geneva Hospital said, BBC News reports.

The vaccine being tested is one developed by NewLink, and recently bought by Merck.

There is currently no vaccine licensed for use to protect against Ebola. Two vaccines are currently being tested in humans in a number of countries.

The side-effects in the Geneva trial were experienced by four volunteers.

The hospital said human safety trials would resume on 5 January in up to 15 volunteers after checks had taken place to ensure the joint pain symptoms were "benign and temporary".

"They are all fine and being monitored regularly by the medical team leading the study," the hospital said.

Four trials of another Ebola vaccine developed by GlaxoSmithKline, in collaboration with the United States National Institute of Allergy and Infectious Diseases, are also underway

Copyright APP (Associated Press of Pakistan), 2014

Comments

Comments are closed for this article.